Download PDF
Thromb Haemost 1975; 34(03): 718-726
DOI: 10.1055/s-0038-1651464
Original Article
Schattauer GmbH

Mini-Dose Heparin[*]

Stanford Wessler
1   Department of Medicine, New York University School of Medicine, New York, N.Y., USA
› Author Affiliations
Further Information

Publication History

Received 22 January 1975

Accepted 12 July 1975

Publication Date:
02 July 2018 (online)

Also available at
    Permissions and Reprints

Summary

Mini-dose heparin has demonstrated a significant decrease in postoperative deep venous thrombosis as manifested by 125I fibrinogen venous limb scans. Whether a similar benefit in lethal pulmonary emboli can be demonstrated is currently under active investigation in England and the Continent. If this European multicenter trial yields a positive result, a safe method for the primary prevention of postoperative pulmonary emboli will have been established. Such a result would encourage evaluation of mini-dose heparin for the prophylaxis of venous thromboembolism among patients with acute myocardial infarction and perhaps for arterial thrombosis complicating coronary arterial bypass surgery.

The late Carl V. Moore, when told of the original Kakkar trial and the rationale behind it, said “well, if it doesn’t work, it ought to!” That may be the way many sympathetic investigators, myself included, feel about mini-dose heparin, but in the end everyone knows that the decisions will be based on hard data.

* Presented at the National Conference on Thrombosis and Hemostasis, American Heart Association, Dallas, Texas, November 22, 1974.


 

  • References

  • 1 Abildgaard U. 1968; Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis. Scandinavian Journal of Clinical and Laboratory Investigation 21: 89.
    CrossrefPubMedGoogle Scholar
  • 2 Ballard R. M. 1973; Low doses of subcutaneous heparin in the prevention of deep venous thrombosis after gynecological surgery. Journal of Obstetrics and Gynecology British Commonwealth 80: 469.
    PubMedGoogle Scholar
  • 3 Barton P. G, Jackson C. M, and Hanahan D. J. 1967; Relationships between Factor V and activated Factor X in the generation of prothrombinase. Nature 214: 923.
    CrossrefPubMedGoogle Scholar
  • 4 Barton P. G, Yin E. T, and Wessler S. 1970; Reactions of activated Factor X: phosphatide mixtures in vitro and in vivo. Journal of Lipid Research 11: 87.
    PubMedGoogle Scholar
  • 5 Bauer G. 1954. Proceedings of the First International Conference on Thrombosis and Embolism. B. Schwabe; Basel: 721.
    Google Scholar
  • 6 Biggs R, Denson K. W. E, Akman N, Borrett R, and Hadden M. 1970; Antithrombin III, antifactor Xa and heparin. British Journal of Haematology 19: 283.
    CrossrefPubMedGoogle Scholar
  • 7 Borsodi A. D, Bradshaw R. A, Rughani I. K, and Bruce R. M. 1975. Structural and functional relationships of human antithrombin III and alpha1-antitrypsin. In: Bradshaw R. A, and Wessler S. (eds.) Heparin: Structure, Function and Clinical Implications. Plenum Press; New York: 249.
    Google Scholar
  • 8 Brinkhous K, Smith H. P, Warner E. D, and Seegers W. H. 1939; The inhibition of blood clotting: an unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin. American Journal of Physiology 125: 683.
    PubMedGoogle Scholar
  • 9 Burstein M. 1955; Sur l’inactivation de la thrombin par le plasma heparine. Archives internationales de Pharmacodynamie et de Therapie 101: 285.
    PubMedGoogle Scholar
  • 10 Burstein M, and Guinand A. 1956; Heparine et consommation de l’antithrombine. Archives internationales de Pharmacodynamie et de Therapie 104: 435.
    PubMedGoogle Scholar
  • 11 Contejean C. 1895; Recherches sur les injections intraveineuses de peptone et leur influence sur la coagulabilite du sang chez le chien. Archives of Physiology and Normal Pathology 7: 45.
    PubMedGoogle Scholar
  • 12 DeTakats G. 1950; Anticoagulants in surgery. Journal of the American Medical Association 142: 527.
    CrossrefPubMedGoogle Scholar
  • 13 Gallus A. S, Hirsh J, Tuttle R. J, Treibilcock R, O’Brien S. E, Carroll J. J, Minden J. H, and Hudechi S. M. 1973; Small subcutaneous doses of heparin in prevention of venous thrombosis. New England Journal of Medicine 288: 545.
    CrossrefPubMedGoogle Scholar
  • 14 Gerendas M. 1960; Thrombin inactivation as an enzymatic process. Thrombosis et Diathesis Haemorrhagica 4: 56.
    PubMedGoogle Scholar
  • 15 Gitel S. 1975. Evidence of a catalytic role of heparin in anticoagulation reactions. In: Bradshaw R. A, and Wessler S. (eds.) Heparin; Structure, Function and Clinical Implications. Plenum Press; New York: 243
    Google Scholar
  • 16 Gordon-Smith I. C, Grundy D. J, LeQuesne L. P, NewCombe J. F, and Bramble F. J. 1972; Controlled trial of two regimens of subcutaneous heparin in prevention of postoperative deep-vein thrombosis. Lancet 1: 1133.
    PubMedGoogle Scholar
  • 17 Grottum K. A, Nordøy A, and Hellem A. 1973; Blood platelet uptake of lipid and effects on platelet functions. Thrombosis et Diathesis Haemorrhagica 29: 701.
    PubMedGoogle Scholar
  • 18 Hanahan D. J, and Papahadjopulos D. 1964. In: Koller F. (ed.) Genetics and the Interaction of Blood Clotting Factors. F. K. Schattauer-Verlag; Stuttgart: 71.
    Google Scholar
  • 19 Howell W. H. 1916; The Coagulation of blood. Harvey Lecture 2: 272.
    PubMedGoogle Scholar
  • 20 Hume H, Sevitt S, and Thomas D. P. 1970. Venous Thrombosis and Pulmonary Embolism. Cambridge, Massachusetts: Harvard University Press; 4.
    Google Scholar
  • 21 Kakkar V. V, Field E. S, Nicolaides A. N, Flute P. T, Wessler S, and Yin E. T. 1971; Prevention of postoperative deep vein thrombosis – prophylactic effects of low doses of heparin. Lancet 2: 699.
    PubMedGoogle Scholar
  • 22 Kakkar V. V, Corrigan T, Spindler J, Fossard D. P, Flute P. T, Crellin R. Q, Wessler S, and Yin E. T. 1972; The efficacy of low doses of heparin in the prevention of deep vein thrombosis following major surgery – a doubleblind, randomized trial. Lancet 2: 101.
    PubMedGoogle Scholar
  • 23 Kakkar V. V. 1973; Low doses of heparin in the prevention of deep veinous thrombosis. Bulletin Swiss Academy of Medical Science 29: 235.
    PubMedGoogle Scholar
  • 24 Lenggenhager K. 1957; Genese und Prophylaxis der postoperativen Fernthrombose. Helvetica Chirurgica Acta 24: 316.
    PubMedGoogle Scholar
  • 25 MacIntyre J. M. C, Vasilescu C, Jones D. R. B, Ruckley C. V. et al. 1974; Heparin versus dextran in the prevention of deep-vein thrombosis. Lancet 2: 118.
    PubMedGoogle Scholar
  • 26 Marciniak E, and Tsukamura S. 1972; Two progressive inhibitors of Factor Xa in human blood. British Journal of Haematology 22: 341.
    CrossrefPubMedGoogle Scholar
  • 27 Markwardt F, and Walsmann P. 1959; The reaction between hirudin and thrombin. Journal of Physiology and Chemistry 317: 64.
    PubMedGoogle Scholar
  • 28 McNicol G. P. 1974; Conventional uses of heparin. Thrombosis et Diathesis Haemorrhagica 33: 97.
    PubMedGoogle Scholar
  • 29 Monkhouse F. D, France E. S, and Seegers W. H. 1955; Studies on antithrombin and heparin cofactor activities of fraction absorbed from plasma by aluminum hydroxide. Circulation Research 3: 397.
    CrossrefPubMedGoogle Scholar
  • 30 Monkhouse F. C, and Milojevic S. 1968; Studies on the relation between plasma antithrombin and heparin-cofactor. Canadian Journal of Physiology and Pharmacology 45: 347.
    PubMedGoogle Scholar
  • 31 Morawitz P. 1905; Die Chemie der Blutgerinnung. Ergebnisse der Physiologie, biologischen Chemie und experimentellen Pharmakologie 4: 307.
    PubMedGoogle Scholar
  • 32 Negus D, Pinto D. J, and Slack W. W. 1971; Effect of small doses of heparin on platelet adhesiveness and lipoproteinlipase activity before and after surgery. Lancet 1: 1202.
    PubMedGoogle Scholar
  • 33 Nicolaides A. N, Dupont P. A, Desai S, Lewis J. D, Douglas J. N, Dodsworth H, FouPviDES G, Luck R. J, and Jamison C. W. 1972; Small doses of subcutaneous sodium heparin in preventing deep venous thrombosis after major surgery. Lancet 2: 890.
    PubMedGoogle Scholar
  • 34 Quick A. J. 1938; Normal antithrombin of blood and its relation to heparin. American Journal of Physiology 123: 712.
    PubMedGoogle Scholar
  • 35 Rosenberg R, and Damus P. S. 1973; The purification and mechanism of action of human antithrombin-heparin cofactor. Journal of Biological Chemistry 248: 6490.
    PubMedGoogle Scholar
  • 36 Seegers W. H, Warner E. D, Brinkhous K. M, and Smith H. P. 1942; Heparin and antithrombotic activity of plasma. Science 96: 300.
    CrossrefPubMedGoogle Scholar
  • 37 Seegers W. H, and Marciniak E. 1962; Inhibition of autoprothrombin C activity with plasma. Nature 193: 1188.
    PubMedGoogle Scholar
  • 38 Seegers W. H, Cole E. R, Harmison C. R, and Monkhouse F. D. 1964; Neutralization of autoprothrombin C activity with antithrombin. Canadian Journal of Biochemistry 42: 359.
    CrossrefPubMedGoogle Scholar
  • 39 Seegers W. H. 1968; Antithrombin: a proteinase inhibitor. Annals of the New York Academy of Science 146: 593.
    CrossrefPubMedGoogle Scholar
  • 40 Sharnoff J. G. 1966; Results in the prophylaxis of postoperative thromboembolism. Surgery, Gynecology and Obstetrics 123: 303.
    PubMedGoogle Scholar
  • 41 Sharnoff J. G, and Kim E. S. 1958; Evaluation of pulmonary megakaryocytes. Archives of Surgery 66: 176.
    PubMedGoogle Scholar
  • 42 Stormorken H. 1969; The platelet release reaction. Its general aspects and relation to phagocytosis/pinocytosis. Scandinavian Journal of Clinical and Laboratory Investigation Supplement 107: 115.
    PubMedGoogle Scholar
  • 43 Vital Statistics of the United States. 1969 Volume II – Mortality Part A. U.S. Department of Health, Education and Welfare, Public Health Service, Health Resources Administration, National Center for Health Statistics, pp. 1-92.
    PubMedGoogle Scholar
  • 44 Waugh D. F, and Fitzgerald M. A. 1956; Quantitative aspects of antithrombin and heparin in plasma. American Journal of Physiology 184: 627.
    PubMedGoogle Scholar
  • 45 Wessler S, Yin E. T, Gaston L. W, and Nicol I. 1967; A distinction between the role of precursor and activated forms of clotting factors in the genesis of stasis thrombi. Thrombosis et Diathesis Haemorrhagica 18: 12.
    PubMedGoogle Scholar
  • 46 Wessler S, and Yin E. T. 1968; The experimental hypercoagulable state induced by Factor X : a comparison of the non-activated and activated forms. Journal of Laboratory and Clinical Medicine 72: 256.
    PubMedGoogle Scholar
  • 47 Wessler S, and Yin E. T. 1969. On the mechanism of thrombosis. In: Brown E, and Moore C.V. (eds.) Progress in Hematology, vol. III. Grune and Stratton; New York,: 201.
    Google Scholar
  • 48 Wessler S, and Yin E. T. 1973; The theory and practice of mini-dose heparin: a status report. Circulation 47: 671.
    CrossrefPubMedGoogle Scholar
  • 49 Wessler S, Kleiger R. E, Cornfield J, and Teitelbaum S. L. 1974; Coumarin therapy in acute myocardial infarction. A Hobson’s choice. Archives of Internal Medicine 134: 774.
    CrossrefPubMedGoogle Scholar
  • 50 Williams H. T. 1971; Prevention of postoperative deep-vein thrombosis with perioperative subcutaneous heparin. Lancet 2: 950.
    PubMedGoogle Scholar
  • 51 Yin E. T, and Wessler S. 1968; Bovine thrombin and activated Factor X: separation and purification. Journal of Biological Chemistry 243: 112.
    PubMedGoogle Scholar
  • 52 Yin E. T, and Wessler S. 1968; Investigation of the apparent thrombogenicity of thrombin. Thrombosis et Diathesis Haemorrhagica 20: 465.
    PubMedGoogle Scholar
  • 53 Yin E. T, and Wessler S. 1969; Evidence for a naturally occurring plasma inhibitor of activated Factor X : its isolation and partial purification. Thrombosis et Diathesis Haemorrhagica 21: 398.
    PubMedGoogle Scholar
  • 54 Yin E. T, and Wessler S. 1970; Heparin-accelerated inhibition of activated Factor X by its natural inhibitor. Biochimica et Biophysica Acta 201: 387.
    CrossrefPubMedGoogle Scholar
  • 55 Yin E. T, Wessler S, and Stoll P. J. 1971; Babbit plasma inhibitor of the activated species of blood coagulation Factor X: purification and some properties. Journal of Biological Chemistry 246: 3694.
    PubMedGoogle Scholar
  • 56 Yin E. T, Wessler S, and Stoll P. J. 1971; Biological properties of the naturally occurring plasma inhibitor to activated Factor X. Journal of Biological Chemistry 246: 3703.
    PubMedGoogle Scholar
  • 57 Yin E. T, Wessler S, and Stoll P. J. 1971; Identity of plasma activated Factor X inhibitor with antithrombin III and heparin cofactor. Journal of Biological Chemistry 246: 3712.
    PubMedGoogle Scholar
  • 58 Yin E. T, Eisenkramer L, and Butler J. V. 1975. Heparin interaction with activated Factor X and its inhibitor. In: Bradshaw B. A, and Wessler S. (eds.) Heparin: Structure, Function and Clinical Implications. Plenum Press; New York: 239.
    Google Scholar